Home/Filings/4/0001490978-25-000036
4//SEC Filing

Akinsanya Karen 4

Accession 0001490978-25-000036

CIK 0001490978other

Filed

Apr 14, 8:00 PM ET

Accepted

Apr 15, 4:31 PM ET

Size

16.0 KB

Accession

0001490978-25-000036

Insider Transaction Report

Form 4
Period: 2025-04-14
Akinsanya Karen
President of R&D, Therapeutics
Transactions
  • Sale

    Common Stock

    2025-04-14$25.11/sh8,378$210,39123,970 total
  • Exercise/Conversion

    Common Stock

    2025-04-14$3.22/sh+13,378$43,07729,003 total
  • Sale

    Common Stock

    2025-04-14$25.11/sh5,000$125,55518,970 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-04-143,3450 total
    Exercise: $2.92Exp: 2027-10-10Common Stock (3,345 underlying)
  • Exercise/Conversion

    Common Stock

    2025-04-14$2.92/sh+3,345$9,76732,348 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-04-1413,3780 total
    Exercise: $3.22Exp: 2028-08-03Common Stock (13,378 underlying)
  • Sale

    Common Stock

    2025-04-14$25.00/sh3,345$83,62515,625 total
Footnotes (6)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.
  • [F2]Includes 15,625 unvested RSUs.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (4) of this form 4.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (4) of this form 4.
  • [F5]The option was granted on August 3, 2018 and is fully vested.
  • [F6]The option was granted on October 10, 2017 and is fully vested.

Issuer

Schrodinger, Inc.

CIK 0001490978

Entity typeother

Related Parties

1
  • filerCIK 0001797672

Filing Metadata

Form type
4
Filed
Apr 14, 8:00 PM ET
Accepted
Apr 15, 4:31 PM ET
Size
16.0 KB